Table 2.
Summary of clinical trials using TCR-engineered αβT cells for paediatric extracranial solid tumours (updated June 2023).
| NCT | Compound | Indication | Age group | Sponsor | Status | Phase | Results |
|---|---|---|---|---|---|---|---|
| NCT03462316 | NY-ESO-1 TCR | Sarcomas | 14–70 years | Sun Yat-sen University | Active, not recruiting | 1 | Not available |
| NCT02775292 | NY-ESO-1 TCR + vaccine therapy + nivolumab | Adult and childhood solid neoplasms | 16 years and older | Jonsson Comprehensive Cancer Center | Completed | 1 | Not available |
| NCT02650986 | NY-ESO-1 TCR/dnTGFbetaRII transgenic T cells | Synovial sarcoma and others | 12 years and older | Roswell Park Cancer Institute | Active, not recruiting | 1, 2 | Only one patient <18 years old. Only toxicity results available. High-grade CRS in four out of 15 patients. |
| NCT01343043 | NY-ESO-1-TCR | Neoplasms | 4 years and older | GlaxoSmithKline | Completed | 1 | CR in one out of 44 patients. 14 PR, 16 SD, and three PD. High-grade CRS in five out of 50 patients. |
| NCT02457650 | NY-ESO-1-TCR | Neuroblastoma, synovial sarcoma, others | 1 year and older | Shenzhen Second People’s Hospital | Unknown | 1 | Data available for four adult patients. One PR, one SD, and two NR. Grade 1–3 adverse events |
| NCT03240861 | NY-ESO-1-TCR | Sarcoma, other NY-ESO-1+ malignancies | 16 years and older | Jonsson Comprehensive Cancer Center | Recruiting | 1 | Not available |
| NCT02869217 | NY-ESO-TCR | Synovial sarcoma and others | 16 years and older | University Health Network, Toronto | Active, not recruiting | 1 | Two PR, five SD, one PD, and one pending. CRS 1/2 in five out of nine patients. |
See the ‘Clinical trial search’ section in supplementary methods for more information regarding search terms.
CR, complete responses; CRS, cytokine release syndrome; NR, non-responder; PD, progressive disease; PR, partial responses; SD, stable disease.